Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
TP Therapeutics, Inc., which operated as Turning Point Therapeutics, was a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies. Their pipeline focused on addressing limitations of existing cancer therapies by targeting common oncogenic drivers of cancer with next-generation kinase inhibitors. A key asset was repotrectinib, a promising ROS1/TRK inhibitor. In August 2022, Turning Point Therapeutics was acquired by Bristol Myers Squibb (BMS) for $4.1 billion, integrating its innovative drug candidates and research platforms into BMS's oncology portfolio.
Served as the primary center for research and development, clinical operations, corporate strategy, and administrative functions for its precision oncology programs.
The headquarters was likely situated in a modern biotech park, equipped with advanced laboratory facilities for drug discovery and development, alongside collaborative office spaces designed to foster innovation.
As a clinical-stage biotech, the work culture was likely dynamic, science-driven, and highly collaborative, with a strong sense of urgency and mission focused on developing impactful cancer treatments for patients.
The San Diego headquarters was crucial for leveraging the rich local biotech ecosystem, including access to talent, research institutions, and service providers, facilitating the advancement of its pipeline.
Prior to its acquisition, Turning Point Therapeutics' global presence was primarily defined by its international clinical trial activities for its oncology drug candidates. These trials often involved sites and investigators across North America, Europe, and Asia-Pacific. Direct operational office presence outside the United States was not significant, with global functions largely managed from their San Diego headquarters.
10628 Science Center Drive, Suite 200
San Diego
California
USA
Address: Not Publicly Detailed
Any minor regional presence would have been to support core functions like clinical trial execution or specific collaborations, rather than fully independent office sites.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Turning Point Therapeutics' leadership includes:
Turning Point Therapeutics has been backed by several prominent investors over the years, including:
The most significant executive event was the acquisition by Bristol Myers Squibb in August 2022, which led to the transition of the entire executive team as an independent entity. Specific individual hires or exits in the 12 months leading up to this were less prominent than the overall change due to the acquisition.
Discover the tools Turning Point Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Bristol Myers Squibb, Turning Point Therapeutics likely used a standard corporate email format such as first initial followed by last name, or first name.last name @tptherapeutics.com. These email addresses are no longer active.
[first_initial][last]@tptherapeutics.com or [first].[last]@tptherapeutics.com
Format
acountouriotis@tptherapeutics.com
Example
0%
Success rate
Bristol Myers Squibb • August 16, 2022
Bristol Myers Squibb announced the successful completion of its acquisition of Turning Point Therapeutics, Inc. This acquisition brings repotrectinib, a next-generation kinase inhibitor, into BMS's oncology portfolio....more
Bristol Myers Squibb • June 3, 2022
Bristol Myers Squibb (NYSE: BMY) and Turning Point Therapeutics, Inc. (NASDAQ: TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share in an all-cash transaction, for a total of $4.1 billion....more
PR Newswire (via Turning Point Therapeutics) • September 16, 2021
Turning Point Therapeutics announced positive topline data from the registrational TRIDENT-1 study of repotrectinib, its lead drug candidate, in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC). The data highlighted strong efficacy and durability....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Turning Point Therapeutics, are just a search away.